Margot Robbie “defines any attempts at lazy categorisation”, says Roisin Kelly in The Times. “Blonde Aussie bombshell and global pin-up? Yes, of course. But she has also become a mogul”: a producer, investor and, as of last month, “now a liquor baron too” – she has started her own gin brand, Papa Salt.
Robbie, 34, is perhaps best known for her starring role in the hit film Barbie, which brought in $1.4 billion, and was produced by a company she founded, LuckyChap, which has racked up 25 Academy Award nominations, 18 Bafta nominations and raked in billions in box-office takings worldwide. Robbie first won fame playing Jordan Belfort’s wife in The Wolf of Wall Street and for her Academy Award-winning role as figure skater Tonya Harding in I, Tonya. Forbes puts her estimated net worth at £46 million.
She has come a long way from humble beginnings, says Julianna Cabili for Tatler Asia. Before making her way to the US, Robbie made a name for herself as a recurring actress in the long-running Australian soap opera Neighbours. She left the series in 2011 to pursue a career in Hollywood. Making it there was more challenging than launching a gin brand, says Robbie. There, you’re basically selling an unproven idea. Gin is at least a tangible product.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Robbie is, of course, “far from the first A-lister to stick her name on a booze brand”, says Kelly. Everyone from Brad Pitt to Ozzy Osbourne has “waded into” the gin industry, a global market worth £12.7 billion. Gary Barlow and Snoop Dogg are making wine, Kendall Jenner has backed a tequila and Cate Blanchett is the creative director of a saké brand. But Robbie and her husband and business partner have no further plans for conquering this world. “Our passions are movies and drinks,” says Robbie. “And now we’ve ticked them both.”
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Lloyds axes foreign currency fees for Club Lloyds customersClub Lloyds customers will be able to withdraw their money abroad without incurring any extra fees
-
How to invest during stagflationTrump’s tariffs look poised to push the global economy into a period of stagflation. We look at how to ensure your investments can survive a global slowdown.
-
Anne Wojcicki: the 'daring' 23andMe CEO who reached too farProfile Anne Wojcicki dreamed of a revolution in personal genomics and medicine and set up 23andMe in 2006. Its collapse into bankruptcy provides a cautionary tale
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
-
Why French far-right leader Marine Le Pen has been banned from running for officeMarine Le Pen, presidential candidate and leader of France's right-wing National Rally party, has been barred from standing by the country's judges.
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
Building firm Keller presents low debt and ample scope for growthGeotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
